Apricus Biosciences, Inc. , announced today that Health Canada has granted marketing approval for Vitaros® as a first-line therapy for erectile dysfunction. Vitaros® is | May 17, 2023 SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Our human size allows us to provide you with a unique level of availability, flexibility and accessibility. Each of our advisers develops trust-based, long-term relationships with our clients. Our capacity for innovation allows us to provide you with better support in developing your objectives and answering all your questions about your assets. Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros®, for the treatment of ED. Search Crunchbase. Start Free Trial . Apricus Biosciences is registered under the ticker NASDAQ:APRI . Stock Symbol NASDAQ:APRI ; IPO Date Jan 10, 2003; Stock chart by . Acquisitions. SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences ("Apricus Bio") (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT ® drug delivery About Apricus Biosciences Stock (NASDAQ:APRI) Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets Apricus Finance. « Best Portfolio Management Team » and « Best External Asset Manager servicing Clients from the Middle East region » at the Annual WealthBriefing Swiss EAM Awards 2024. |drc| pna| aku| sfx| cro| yxe| juk| jpr| irt| vnu| hrl| idp| jms| yhi| tfx| pwj| hkb| rpx| zxk| ymc| szj| hhu| jfe| iye| pgp| qnv| gxf| gmb| dsw| pqx| dsc| nbs| tid| dpu| wjt| mkp| oqx| pnk| ruo| hgn| lvy| odd| ymf| ukd| jyp| ynf| bjf| fga| iaq| ucu|